These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 7527735

  • 1. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer.
    Miyanaga N, Akaza H, Shimazui T, Ohtani M, Koiso K.
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S5-8. PubMed ID: 7527735
    [Abstract] [Full Text] [Related]

  • 2. Results of adjuvant chemotherapy for invasive urothelial cancer with lymph-node metastasis.
    Kobayashi H, Obata K.
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S14-7. PubMed ID: 7994781
    [Abstract] [Full Text] [Related]

  • 3. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
    Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N.
    Cancer; 1989 Dec 15; 64(12):2448-58. PubMed ID: 2819654
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ, Elson P, Dreicer R, Hahn R, Nichols CR, Williams R, Einhorn LH.
    J Clin Oncol; 1994 Mar 15; 12(3):483-8. PubMed ID: 7509853
    [Abstract] [Full Text] [Related]

  • 10. Long-term results with M-VAC for advanced urothelial cancer: high relapse rate and low survival in patients with a complete response.
    Igawa M, Urakami S, Shiina H, Ishibe T, Kadena H, Usui T.
    Br J Urol; 1995 Sep 15; 76(3):321-4. PubMed ID: 7551840
    [Abstract] [Full Text] [Related]

  • 11. [Clinical evaluation of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy for advanced urothelial cancer].
    Mikami K, Nakagawa S, Takada H, Ebisui K, Sugimoto K, Watanabe H, Maegawa M, Nakao M.
    Hinyokika Kiyo; 1994 Apr 15; 40(4):303-7. PubMed ID: 8191968
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity].
    Igawa M, Kadena H, Ohkuchi T, Ueda M, Usui T.
    Nihon Hinyokika Gakkai Zasshi; 1991 Oct 15; 82(10):1627-36. PubMed ID: 1770701
    [Abstract] [Full Text] [Related]

  • 14. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer.
    Kuroda M, Meguro N, Maeda O, Saiki S, Kinouchi T, Usami M, Kotake T.
    Cancer Chemother Pharmacol; 1994 Oct 15; 35 Suppl():S9-13. PubMed ID: 7527736
    [Abstract] [Full Text] [Related]

  • 15. Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. A randomized study.
    Pizzocaro G, Milani A, Piva L, Faustini M, Spino E.
    Eur Urol; 1991 Oct 15; 20(2):89-92. PubMed ID: 1752280
    [Abstract] [Full Text] [Related]

  • 16. [M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced renal pelvic and ureteral carcinoma].
    Igawa M, Ueki T, Ueda M, Okada K, Usui T, Ohnishi Y, Kume T, Masu C, Ishino T, Nakatsu H.
    Gan To Kagaku Ryoho; 1989 Aug 15; 16(8 Pt 1):2577-82. PubMed ID: 2673046
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group.
    Kuroda M, Kotake T, Akaza H, Hinotsu S, Kakizoe T.
    Jpn J Clin Oncol; 1998 Aug 15; 28(8):497-501. PubMed ID: 9769784
    [Abstract] [Full Text] [Related]

  • 18. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
    Hibi H, Okamura K, Takashi M, Shimoji T, Miyake K.
    Hinyokika Kiyo; 1997 Feb 15; 43(2):89-96. PubMed ID: 9086342
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer.
    Dodd PM, McCaffrey JA, Mazumdar M, Scher H, Higgins G, Boyle MG, Herr H, Bajorin DF.
    Cancer Invest; 2000 Feb 15; 18(7):626-34. PubMed ID: 11036470
    [Abstract] [Full Text] [Related]

  • 20. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A, Flex D, Gafni D, Rabinovitz O, Sulkes A, Baniel J.
    Harefuah; 1999 Feb 15; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.